Navigation Links
Quinton Oswald Named Chief Executive Officer of SARcode Corporation
Date:9/14/2010

BRISBANE, Calif., Sept. 14 /PRNewswire/ -- SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced that Quinton Oswald has joined the company as Chief Executive Officer.

Mr. Oswald brings significant commercial experience and management expertise to the CEO role. Most recently at Genentech, where he served as the Vice President & Business Unit Head for the Tissue Growth and Repair Business, Mr. Oswald was responsible for four key franchises – Ophthalmology, Growth Hormone, Fibrinolytics and Cystic Fibrosis – generating over $2.1 billion in annual sales. During his tenure at Genentech, Mr. Oswald oversaw the successful commercial launch of Lucentis® (ranibizumab) in 2006, the third fastest new product introduction in U.S. pharma history. Lucentis® was approved for the treatment of neovascular (wet) age-related macular degeneration (AMD) and reached sales of over $1 billion in 2009. This breakthrough therapy dramatically changed the treatment paradigm for retinal specialists by offering their patients the ability to stabilize and improve vision, instead of facing a progressive course toward blindness.

Prior to Genentech, Mr. Oswald led the North American Ophthalmology business for Novartis, which in conjunction with QLT, Inc. pioneered Visudyne® (verteporfin), the first drug treatment for wet AMD. Launched in 2000, Visudyne® replaced thermal laser therapy, offering a more targeted and less damaging treatment to slow vision decline.

"We are very pleased to have Quinton join our team at SARcode," said Robert Alexander, Director at Alta Partners and member of the SARcode Board of Directors. "He brings the right combination of sector knowledge and commercial expertise needed to lead SARcode through Phase III trials and on to the market. Quinton is a perfect fit for this role, given his long history in the ophthalmology space and his success in launching Lucentis®. While at Genentech, Quinton worked alongside Charles Semba, the Development Team Leader for Lucentis®, who today serves as SARcode's Chief Medical Officer. We expect this team will continue our rapid progress in the clinic, and guide our lead compound quickly through our final pivotal trials."

"I am very fortunate to have the opportunity to lead a company with the potential to deliver significant beneficial impact in a therapeutic area in which I not only have many years of operational experience, but also a passion to improve upon existing treatment," said Mr. Oswald, Chief Executive Officer of SARcode.  "There are more than 20 million patients suffering from dry eye in the U.S. alone and up to 50 million patients worldwide. Yet most of them receive little relief from currently available drugs.  Our lead product candidate, SAR 1118, has provided excellent Phase II results in both signs and symptoms. The study achieved these results within 12 weeks, demonstrating potential for more rapid relief than currently available therapies. I see big opportunities for this product and SARcode, and I am looking forward to being a part of this team."

Before joining Novartis, Mr. Oswald spent 16 years with Bristol Myers Squibb. After beginning his tenure with Bristol Myers in his home country of South Africa, he moved to Holland as General Manager to merge Bristol Myers and Squibb. Relocating to the U.S. in 1993, Mr. Quinton held line management roles as President for Asia, Middle East, and Africa, and President for Latin America and Canada.

About SARcode Corporation

SARcode is a venture-backed biopharmaceutical company focused on the development of best in class small molecule LFA-1 antagonists as novel nonsteroidal immunomodulators/anti-inflammatory agents for the treatment of T-cell mediated inflammatory diseases. Institutional investors include Alta Partners and Clarus Ventures.

For contact information, visit www.sarcode.com


'/>"/>
SOURCE SARcode Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Despite Economic Turmoil, CIS Named to Inc. 5000 List of Fastest-Growing Private Companies in America
2. James F. Szigethy Named Curemarks Director of New Product Development
3. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
4. Cape Medical Supply Named to Prestigious Inc. 5000 List of Americas Fastest Growing Private Companies for Fourth Year in a Row
5. SAM Medical Products Named to Inc. 5000 List of the Fastest-Growing Private Companies in America
6. MedNet Solutions Named to the Inc. 5000 List of Fastest Growing Companies for the Fourth Consecutive Year
7. BlueDot Medical, Inc. Named to 2010 Inc. 500/5000
8. KPaul Named to the Inc. 500 Fastest Growing Companies List for 2010
9. Hardy Diagnostics Named in Inc. 5000
10. ITelagen Named to Prestigious 2010 Inc. 5000 List of Fastest-Growing Companies
11. Obama Named the Most Powerful Person in Healthcare for Second Consecutive Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):